AMPA receptor potentiators as novel antidepressants

Current Pharmaceutical Design

Volumn 11, Issue 12, 2005, Pages 1511-1527

  Alt, Andrew ^a   Witkin, J M ^a   Bleakman, D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

AMPA receptors; BDNF; Brain derived neurotrophic factor; Depression; LY392098; LY404187; LY451646; Neurogenesis

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; 7 CHLORO 3,4 DIHYDRO 3 METHYL 2H 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; ANIRACETAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOTHIAZIDE; DIAZOXIDE; DULOXETINE; FLUOXETINE; IMIPRAMINE; IPRONIAZID; LY 392098; LY 404187; LY 451646; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; N 2 [4 (3 THIENYL)PHENYL]PROPYL 2 PROPANESULFONAMIDE; N 2 [4 (4 CYANOPHENYL)PHENYL]PROPYL 2 PROPANESULFONAMIDE; N METHYL DEXTRO ASPARTIC ACID; NISOXETINE; PIRACETAM; ROLIPRAM; SEROTONIN UPTAKE INHIBITOR; SULFONAMIDE; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

BINDING AFFINITY; DEPRESSION; DISEASE MODEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; IN VIVO STUDY; MONOAMINERGIC SYSTEM; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TISSUE DISTRIBUTION;

ALLOSTERIC REGULATION; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; GENE EXPRESSION REGULATION; HUMANS; NERVOUS SYSTEM; NEUROPROTECTIVE AGENTS; RECEPTORS, AMPA; STRESS, PSYCHOLOGICAL;

EID: 18844380431     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053764814     Document Type: Review

References (152)

1. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999; 375: 31-40.
2. Selikoff IJ, Robitek EH, Orenstein GG. Treatment of pulmonary tuberculosis with hydrazine derivatives of isonicotinic acid. J Am Med Assoc 1952; 973-80.
3. Ban TA. Pharmacotherapy of mental illness - a historical analysis. Prog Neuro-Psychopharmacol Biol Psychiatry 2001; 25: 709-27.
4. Drevets WC. Neuroimaging and neuropathological studies of depression: Implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 2001; 11: 240-9.
5. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001; 7: 541-7.
6. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34: 13-25.
7. Asberg M, Traskman L, Thoren P. 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor? Arch Gen Psychiatry 1976; 33: 1193-7.
8. Mann JJ, Arango V, Marzuk PM, Theccanat S, Reis DJ. Evidence for the 5-HT hypothesis of suicide. A review of post-mortem studies. Br J Psychiatry 1989; 8 (suppl): 7-14.
9. Risch SC, Nemeroff CB. Neurochemical alterations of serotonergic neuronal systems in depression. J Clin Psychiatry 1992; 53 (suppl): 3-7.
10. Wong DT, Bymaster FP, Engelman E. Prozac (Fluoxetine, Lilly 110140), the first selective serotoin reuptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 1995; 57: 411-41.
11. Frank L, Revicki DA, Sorensen SV, Shih YC. The economics of selective serotonin reuptake inhibitors in depression: a critical review. CNS Drugs 2001; 15: 59-83.
12. Richelson E. Pharmacology of antidepressants - characteristics of the ideal drug. Mayo Clin Proc 1994; 69: 1069-81.
13. Modell JG, Katholi CR, Modell JD, DePalma RA. Comparative sexual side effects of bupropion, fluoxetine, paraoxetine, and sertraline. Clin Pharm Ther 1997; 61: 476-87.
14. Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry 1999; 60 (suppl 4): 4-11.
15. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Gilman AG, Rall TW, Nies AS, Taylor P Eds, Goodman and Gilman'+s The Pharmacological Basis of Thereapeutics, 8th ed. New York, Pergamon Press 1990; 383-435.
16. Sporn J, Balanoof JK, Schatzberg A, Charney DS. Principles of the pharmacotherapy of depression. In: Charney DS, Nestler EJ Eds, Neurobiology of Mental Illness, 2nd ed. Oxford, Oxford University Press 2004; 491-511.
17. Oswald I, Brezinova V, Dunleavy DLF. On the slowness of action of tricyclic antidepressant drugs. Br J Psychiatry 1972; 120: 673-7.
18. Stassen HH, Angst J. Delayed onset of action of antidepressants: factor fiction? CNS Drugs 1998; 9: 177-84.
19. Nelson JC. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry 1999; 46: 1301-8.
20. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 1994; 17: 31-108.
21. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999; 51: 7-61.
22. Schoepp DD, Conn PJ. Metabotropic glutamate receptors. Pharmacol Biochem Behav 2002; 74: 255-6.
23. Lerma J, Paternain AV, Rodríguez-Moreno A, López-García JC. Molecular physiology of kainate receptors. Physiol Rev 2001; 81: 971-98.
24. Collingridge GL, Lester RAJ. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol Rev 1989; 40: 143-210.
25. Hayashi T, Umemori H, Mishina M, Yamamoto T. The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn. Nature 1999; 397: 72-6.
26. Partin KM, Fleck MW, Mayer ML. AMPA receptor flip/flop mutants affecting deactivation, desensitization, and modulation by cyclothiazide, aniracetam and thiocyanate. J Neurosci 1996; 16: 6634-47.
27. Bleakman D, Lodge D. Neuropharmacology of AMPA and kainate receptors. Neuropharmacology 1998; 37: 1187-204.
28. Witkin JM, Kaminski R, Rogawski MA. Pharmacology of glutamate receptors. In: Herman BH, et al. Eds, Glutamate and Addiction. Totowa, Humana Press. 2002; 23-49.
29. Quirk JC, Nisenbaum ES. Multiple determinants for allosteric modulation of alternatively spliced AMPA receptors. J Neurosci 2003; 23: 10953-62.
30. Vizi ES, Mike A, Tarnawa I. 2, 3-benzodiazepines (GYK152466 and analogs): negative allosteric modulators of AMPA receptors. CNS Drug rev 1996; 2: 91-126.
31. Ito I, Tanabe S, Kohda A, Sugiyama H. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J Physiol 1990; 424: 533-43.
32. Copani A, Genazzani AA, Aleppo G, Casabona G, Canonico PL, Scapagnini U, et al. Nootropic drugs positively modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal cultures. J Neurochem 1992; 58: 1199-204.
33. Staubli U, Ambros-Ingerson J, Lynch G. Receptor changes and LTP: an analysis using aniracetam, a drug that reversibly modifies glutamate (AMPA) receptors. Hippocampus 1992; 2: 49-57.
34. Arai A, Kessler M, Xiao P, Ambros-Ingerson J, Rogers G, Lynch GA. A centrally active drug that modulates AMPA receptor gated currents. Brain Res 1994; 638: 343-6.
35. Yamada KA, Rothman SM. Diazoxide blocks glutamate desensitization and prolongs excitatory postsynaptic currents in rat hippocampal neurons. J Physiol 1992; 458: 409-23.
36. Patneau DK, Vyklicky L Jr, Mayer ML. Hippocampal neurons exhibit cyclothiazide-sensitive rapidly desensitizing responses to kainate. J Neurosci 1993; 13: 3496-509.
37. Thompson DM, Guidotti A, DiBella M, Costa E. 7-chloro-3-methyl-3, 4-dihydro-2H-l, 2, 4-benzothiadiazine S, S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in paras monkeys. Proc Natl Acad Sci USA 1995; 92: 7667-71.
38. Sekiguchi M, Fleck MW, Mayer ML, Takeo J, Chiba Y, Yamashita S, et al. A novel allosteric potentiator of AMPA receptors: 4-[2-(phenylsulfonylamino)ethylthio]-2, 6-difluoro-phenoxyacetamide. J Neurosci 1997; 17: 5760-71.
39. Ornstein PL, Zimmerman DM, Arnold MB, Bleisch TJ, Cantrell B, Simon R, et al. Biarylpropylsulfonamides as novel, potent potentiators of 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)-propanoic acid (AMPA) receptors. J Med Chem 2000; 43: 4354-8.
40. Miu P, Jarvie KR, Radhakrishnan V, Cates MR, Ogden A, Ornstein PL, et al. Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro. Neuropharmacology 2001; 40: 976-83.
41. Angulo MC, Lambolez B, Audinat E, Hestrin S, Rossier J. Subunit composition, kinetic, and permeation properties of AMPA receptors in single neocortical nonpyramidal cells. J Neurosci 1997; 17: 6685-96.
42. Gates M, Ogden A, Bleakman D. Pharmaeological effects of AMPA receptor potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in vitro. Neuropharmacology 2001; 40: 984-91.
43. Duman RS. Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 1998; 44: 324-35.
44. Duman RS. The neurochemistry of depressive disorders: preclinical studies. In Charney DS, Nestler EJ Eds, Neurobiology of Mental Illness, 2nd ed. Oxford, Oxford University Press 2004; 421-60.
45. Skolnick P, Legutko B, Li X, Bymaster FP. Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol Res 2001; 43: 411-43.
46. Porsolt RD, Pichon ML, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977; 266: 730-2.
47. Borsini F, Meli A. Is the forced swim test a suitable model for revealing antidepressant activity? Psychopharmacology 1998; 94: 147-60.
48. Li X, Tizzano JP, Griffey K, Clay M, Lindstrom T, Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001; 40: 1028-33.
49. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: Recent developments and future needs. Trends Pharmacol Sci 2002; 23: 238-45.
50. Bai F, Li X, Clay M, Lindstrom T, Skolnick P. Intra- and interstrain differences in models of "behavioral despair". Pharmacol Biochem Behav 2001; 70: 187-92.
51. Knapp RJ, Goldenberg R, Shuck C, Cecil A, Watkins J, Miller C, et al. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol 2002; 440: 27-35.
52. Malatynska E, Goldenberg R, Shuck L, Haque A, Zamecki P, Crites G, et al. Reduction of submissive behavior in rats: a test for antidepressant drug activity. Pharmacology 2002; 64: 8-17.
53. Li X, Witkin JM, Need AB, Skolnick P. Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cell Mol Neurobiol 2003; 23: 419-30.
54. Beyer JL, Krishnan KR. Volumetric brain imaging findings in mood disorders. Bipolar Disord 2002; 4: 89-104.
55. Strakowski SM, Adler CM, DelBello MP. Volumetric MRI studies of mood disorders: Do they distinguish unipolar and bipolar disorder? Bipolar Disord 2002; 4: 80-8.
56. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psyciatry 2000; 48: 766-7.
57. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001; 58: 545-53.
58. Coyle JT, Schwarcz R. Mind glue: Implications of glial cell biology for psychiatry. Arch Gen Psychiatry 2000; 57: 90-3.
59. Haydon PG. Glia: Listening and talking to the synapse. Nat Rev Neurosci 2001; 2: 185-93.
60. Ullian EM, Sapperstain SK, Christopherson KS, Barres BA. Control of synapse number by glia. Science 2001; 291: 657-61.
61. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996; 93: 3908-13.
62. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, Gray NA, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003; 53: 707-42.
63. D'Sa C, Duman R. Antidepressants and neurpolasticity. Bipolar Disord 2002; 4: 183-94.
64. Sapolsky RM. Stress, glucocorticoids, and damage to the nervous system: The current state of confusion. Stress 1996; 1: 1-19.
65. McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci 1999; 22: 105-22.
66. Gould E, Cameron HA. Regulation of neuronal birth, migration and death in the rat dentate gyrus. Dev Neurosci 1996; 18: 22-35.
67. Gould E, McEwen BS, Tanapat P, Galea LAM, Fuchs E. Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. J Neurosci 1997; 17: 2492-8.
68. Gould E, Tanapat P, McEwen BS, Flügge G, Fuchs E. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc Natl Acad Sci USA 1998; 95: 3168-71.
69. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-10.
70. Madsen TM, Treschow A, Bengzon J, Bolwig TG, Lindvall O, Tingström A. Increased neurogenesis in a model of electroconvulsive therapy. Biol Psychiatry 2000; 47: 1043-9.
71. Wahlund B, von Rosen D. ECT of major depressed patients in relation to biological and clinical variables: a brief overview. Neuropsychopharmacology 2003; 28 (suppl): S21-6.
72. Santarelli L, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-9.
73. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-47.
74. Smith MA, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995; 15: 1768-77.
75. Nibuya M, Takahashi M, Russell DS, Duman RS. Repeated stress increases catalytic TrkB mRNA in rat hippocampus. Neurosci Lett 1999; 267: 814.
76. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16: 2365-72.
77. Fujimaki K, Morinobu S, Duman RS. Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus. Neuropsychopharmacology 2000; 22: 42-51.
78. Smith MA, Zhang LX, Lyons WE, Mamounas LA. Anterograde transport of endogenous brain-derived neurotrophic factor in hippocampal mossy fibers. Nuroreport 1997; 8: 1829-34.
79. Neeper SA, Gómez-Pinilla F, Choi J, Cotman CW. Exercise and brain neurotrophins. Nature 1995; 373: 109.
80. Neeper SA, Gomez-Pinilla F, Choi J, Cotman CW. Physical activity increases mRNA for brain-derived neurotrophic factor and nerve growth factor in rat brain. Brain Res 1996; 726: 49-56.
81. Labb EE, Welsh MC, Delaney D. Effects of consistent aerobic exercise on the psychological functioning of women. Percept Mot Skills 1988; 67: 919-25.
82. Hill RD, Storandt M, Malley M. The impact of long-term exercise training on psychological function in older adults. J Gerontol 1993; 48: 12-7.
83. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant- like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 1997; 56: 131-7.
84. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22: 3251-61.
85. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E, et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003; 23: 349-57.
86. Saarelainen T, Lukkarinen JA, Grohn OH, Jolkkonen J, Koponen E, Haapasalo A, et al. Transgenic mice overexpressing truncated trkB neurotrophin receptors in neurons show increased susceptibility to cortical injury after focal cerebral ischemia. Mol Cell Nurosci 2000; 16: 87-96.
87. Coppell AL, Pei Q, Zetterström TSC. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 2003; 44: 903-910.
88. Dias BG, Banerjee SB, Duman RS, Vaidya VA. Differential regulation of Brain Derived Neurotrophic Factor transcripts by antidepressant treatments in the adult rat brain. Neuropharmacology 2003; 45: 553-63.
89. Miró X, Pérez-Torres S, Artigas F, Puigdomènech P, Palacios JM, Mengod G. Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study. Neuropharmacology 2002; 43: 1148-57.
90. Blendy JA, Kaestner KH, Schmid W, Gass P, Schutz G. Targeting of the CREB gene leads to up-regulation of a novel CREB mRNA isoform. EMBO J 1996, 15: 1098-106.
91. Conti AC, Cryan JF, Dalvi A, Lucki I, and Blendy JA. cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 2002; 22: 3262-8.
92. O'Neil MF, Moore NA. Animal models of depression: Are there any? Hum Psychopharmacol Clin Exp 2003; 18: 239-54.
93. 2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 1998; 20: 709-23.
94. 2+ /calmudulin- as well as cAMP-dependent protein kinase. Proc Natl Acad Sci USA 1991; 5061-5.
95. Armstrong RC, Montminy MR. Transsynaptic control of gene expression. Annu Rev Neurosci 1993; 16: 17-29.
96. 2+- regulated transcription factor phosphorylated by CaM kinases. Science 1991; 252: 1427-30.
97. Matthews RP, Guthrie CR, Wailes LM, Zhao X, Means AR, McKnight GS. Calcium/calmodulin-dependent protein kinase types II and IV differentially regulate CREB-dependent gene expression. Mol Cell Biol 1994; 14: 6107-16.
98. 2+- and stimulus duration-dependent switch for hippocampal gene expression. Cell 1996; 87: 1203-14.
99. 2+ signaling pathways converge on CaM kinase in PC12 cells. FEBS Lett 1992; 304: 237- 40.
100. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54: 597-606.
101. Wang YY, Aghajanian GK. Excitation of locus coeruleus neurons by an adenosine 3′, 5′-cyclic monophosphate-activated inward current: extracellular and intracellular studies in rat brain slices. Synapse 1987; 1: 481-7.
102. Zafra F, Hengerer B, Leibrock J, Thoenen H, Lindholm D. Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. EMBO J 1990; 9: 3545-50.
103. Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM. Positive modulation of AMPA receptors increases neutrophin expression by hippocampal and cortical neurons. J Neurosci 2000; 20: 8-21.
104. Xing J, Ginty DD, Greenberg ME. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 1996; 273: 959-63.
105. Roberson ED, English JD, Adams JP, Selcher JC, Kondratick C, Sweatt JD. The mitogen-activated protein kinase cascade couples PKA and PKC to cAMP response element binding protein phosphorylation in area CA 1 of hippocampus. J Neurosci 1999; 19: 4337-48.
106. Watabe AM, Zaki PA, O'Dell TJ. Coactivation of β-adrenergic and cholinergic receptors enhances the induction of long-term potentiation and synergistically activates mitogen-activated protein kinase in the hippocampal CA1 region. J Neurosci 2000; 20: 5924- 31.
107. Patpoutian A, Reichardt LF. Trk receptors: Mediators of neurotrophin action. Curr Opin Neurobiol 2001; 11: 272-80.
108. Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci 2001; 2: 24-32.
109. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent l-methyl-4- phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91: 5104-8.
110. Mamounas LA, Blue ME, Siuciack JA, Altar CA. Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J Neurosci 1995; 15: 7929-39.
111. Patel MN, McNamara JO. Selective enhancement of axonal branching of cultured dentate gyrus neurons by neurotrophic factors. Neuroscience 1995; 69: 763-70.
112. Lowenstein DH, Arsenault L. Dentate granule cell layer collagen explant cultures: spontaneous axonal growth and induction by brain-derived neurotrophic factor or basic fibroblast growth factor. Neuroscience 1996; 74: 1197-208.
113. Vaidya VA, Siuciak JA, Du F, Duman RS. Hippocampal mossy fiber sprouting induced by chronic electroconvulsive Seizures. Neuroscience 1999; 89: 157-66.
114. Manji HK, Moore GJ, Chen G. Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers. Br J Psychiatry 2001; 178 (suppl 41): S107-19.
115. Chen DF, Schneider GE, Martinou JC, Tonegawa S. Bcl-2 promotes regeneration of severed axons in mammalian CNS. Nature 1997; 385: 434-9.
116. Chen DF, Tonegawa S. Why do mature CNS neurons of mammals fail to re-establish connections following injury - functions of bcl-2. Cell Death Differ 1998; 5: 816-22.
117. Chierzi S, Strettoi E, Cenni MC, Maffei L. Optic nerve crush: axonal responses in wild-type and bcl-2 transgenic mice. J Neurosci 1999; 19: 8367-76.
118. Holm KH, Cicchetti F, Bjorklund L, Boonman Z, Tandon P, Costantini LC, et al. Enhanced axonal growth from fetal human bcl-2 transgenic mouse dopamine neurons transplanted to the adult rat striatum. Neuroscience 2001; 104: 397-405.
119. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999; 286: 1358-62.
120. Finkbeiner S. CREB couples neurotrophin signals to survival messages. Neuron 2000; 25: 11-4.
121. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37-40.
122. Sweatt J. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 2001; 76: 1-10.
123. Palmer TD, Takahashi J, Gage FH. The adult rat hippocampus contains primordial neural stem cells. Mol Cell Neurosci 1997; 8: 389-404.
124. Pencea V, Bingaman KD, Wiegand SJ, Luskin MB. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci 2001; 21: 6706- 17.
125. Zigova T, Pencea V, Wiegand SJ, Luskin MB. Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. Mol Cell Neurosci 1998; 11: 234-45.
126. Duman RS, Nakagawa S, Malberg J. Regulation of adult neuro-genesis by antidepressant treatment. Neuropsychopharmacology 2001; 25: 836-44.
127. Lindefors N, Ballarin M, Ernfors P, Falkenberg T, Persson H. Stimulation of glutamate receptors increases expression of brain-derived neurotrophic factor mRNA in rat hippocampus. Ann NY Acad Sci 1992; 648: 296-9.
128. Legutko B, Li X, Skolnick P. Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator. Neuropharmacology 2001; 40: 1019-27.
129. Mackowiak M, O'Neill M, Hicks C, Bleakman D, Skolnick P. An AMPA receptor potentiator modulates hippocampal expression of BDNF: An in vivo study. Neuropharmacology 2002; 43: 1-10.
130. Bai F, Bergeron M, Nelson DL. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology 2003; 44: 1013-21.
131. Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J Neurosci 1996; 16: 2027-33.
132. Parent JM, Yu TW, Leibowitz RT, Geschwind DH, Sloviter RS, Lowenstein DH. Dentate granule cell neurogenesis is increased by Seizures and contributes to aberrant network reorganization in the adult rat hippocampus. J Neurosci 1997; 17: 3727-38.
133. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000; 75: 1729-34.
134. Murray TK, Whalley K, Robinson CS, Ward MA, Hicks CA, Lodge D, et al. LY503430, a novel α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J Pharmacol Exp Ther 2003; 306: 752-62.
135. Benowitz LI, Routtenberg A. GAP-43: an intrinsic determinant of neuronal development and plasticity. Trends Neurosci 1997; 20: 84-91.
136. Namgung U, Routtenberg A. Transcriptional and post-transcriptional regulation of a brain growth protein: regional differentiation and regeneration induced by GAP-43. Eur J Neurosci 2000; 12: 3124-36.
137. Abramets II, Kuznetsov YV, Samoilovich IM. Changes of properties of glutamatergic synapses in the hippocampus of rats with behavioral depression and modeling of the changes in vitro. Neurophysiology 2001; 33: 294-303.
138. Okano K, Kuraishi Y, Satoh M. Effects of repeated cold stress on aversive responses produced by intrathecal excitatory amino acids in rats. Biol Pharm Bull 1995; 18: 1602-4.
139. Stalnaker TA. Berridge CW. AMPA receptor stimulation within the central nucleus of the amygdala elicits a differential activation of central dopaminergic systems. Neuropsychopharmacology 2003; 28: 1923-34.
140. Bartanusz V, Aubry J-M, Pagliusi S, Jezova D, Baffi J, Kiss JZ. Stress-induced changes in messenger RNA levels of N-methyl-D- aspartate and AMPA receptor subunits in selected regions of the rat hippocampus anal hypothalamus. Neuroscience 1995; 66: 247-52.
141. Watanabe Y, Weiland NG, McEwen BS. Effects of adrenal steroid manipulations and repeated restraint stress on dynorphin mRNA levels and excitatory amino acid receptor binding in hippocampus. Brain Res 1995; 680: 217-25.
142. Meador-Woodruff JH, Hogg AJ Jr, Smith RE. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res Bull 2001; 55: 631-40.
143. Martinez-Turrillas R, Freschilla D, Del Rio J. Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus. Neuropharmacology 2002; 43: 1230-7.
144. Hemmings HC Jr, Greengard P, Tung HY, Cohen P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-l. Nature 1984; 310: 503-5.
145. Bibb JA, et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 1999; 402: 669-71.
146. Svenningsson P, Tzavara ET, Witkin J, Fienberg AA, Nomikos GG, Greengard P. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci USA 2002; 99: 3182-7.
147. Yan Z, Hsieh-Wilson L, Feng J, Tomizawa K, Allen PB, Fienberg AA, et al. Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin. Nat Neurosci 1999; 2: 13-7.
148. Snyder GL, Allen PB, Fienberg AA, Valle CG, Huganir RL, Naim AC, et al. Regulation of phosphorylation of the GluRI AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo. J Neurosci 2000; 20: 4480-8.
149. Lee H-K, Barbarosie M, Kameyama K, Bear MF, Huganir RL. Regulation of distinct AMPA receptor phosphorylation sites during bi-directional synaptic plasticity. Nature 2000; 405: 955-9.
150. Nowak JZ, Zawilska JB. PACAP in avians: origin, occurrence, and receptors - pharmacological and functional considerations. Curr Pharm Design 2003; 9(6): 467-81.
151. Tanaka K, Ogawa N. Possibility of non-immunosuppressive immunophilin ligands as potential therapeutic agents for Parkinson's disease. Curr Pharm Design 2004; 10(6): 669-77.
152. van Waarde A, Vaalburg W, Doze P, Bosker FJ, Elsinga PH. PET imaging of beta-adrenoceptors in human brain: a realistic goal or a mirage? Curr Pharm Design 2004; 10(13): 1519-36.